FDA rejects Noven's copycat version of Duragesic pain patch

Miami-based Noven Pharmaceuticals said the FDA has rejected its generic version of a Duragesic pain patch, saying that higher concentrations of the drug might make it less safe. Noven and its partner, Endo, met with regulators yesterday. The FDA announced in July that it was investigating reported deaths and side effects linked to the Durgesic patch and other copycats on the market. Noven said it disagreed with the FDA's conclusion and would study how it might obtain approval for the product.

- read this AP story for more

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.